With an impressive response across all categories, Indegene's IPO was fully booked on the first day. The non-institutional investor category reached 4.13 times subscription, while the retail portion subscribed 1.50 times. The quota for the employees received is 1.31 times the subscription. According to BSE data, subscription status for Indegene's IPO is at 1.67 times per day.
The proportion of qualified institutional buyers is 5%. Indegene's IPO, which opened for subscription today (Monday 6 May), will close on Wednesday 8 May.
The company provides digitally driven commercialization services to the life sciences sector, which includes biopharmaceutical, emerging biotechnology and medical device companies, across drug development and clinical trials, regulatory filings, pharmacovigilance and complaint management, and product sales and marketing.
Also Read: Indegene IPO opens: GMP, subscription status, verification, price, date, lot size, other details. Apply or not?
As of December 31, 2023, there were 65 active customers of the Company. With operational centers in Europe, Asia and North America, the organization offers them solutions. Their self-developed proprietary platforms powered by machine learning (ML) and artificial intelligence (AI) enable them to deploy our solutions at scale around the globe.
The ₹Indigene's ₹1,841.76 crore IPO consists of an offer for sale (OFS) of 23,932,732 shares by the selling investor investor and a fresh issue of ₹760 crore.
Also Read: Indegene IPO: The issue has been recorded at 1.30 times on the first day so far. NII, retail share oversubscribed; Check GMP and subscription status
Here are some of the key risks listed by the company in its Red Herring Prospectus (RHP):
- Because the Company focuses exclusively on the life sciences sector, it may be negatively affected by trends, outsourcing and other variables specific to the life sciences sector.
- The Company's business and profitability depend on factors affecting the life sciences industry and its ongoing relationships with these key customers, as it focuses primarily on the life sciences sector and allocates a significant portion of its business to a select group of Major customers based in this area owe credit to North America and Europe.
- Potential investors may not be familiar with the revenue and business concepts.
- The majority of the company's revenue comes from its subsidiaries. Any interruption in the business activities of one or more of its subsidiaries could have a negative impact on their operations, finances and the Company's overall performance.
- Life science activities are very competitive and their future is difficult to predict.
Also Read: Indegene IPO starts next week. GMP, valuation, price, more details about the upcoming IPO in 10 points
- It is possible that disaster recovery and business continuity strategies are inadequate. The organization's business, financial condition and results of operations could be adversely affected if there is an interruption that was not contemplated in the business continuity and disaster recovery plans or if the organization is unable to ensure the timely restoration of critical services .
- Your margins could change due to delays in revenue recognition.
- The Company's business prospects, reputation and future financial performance may be adversely affected if it is unable to control turnover and attract and retain qualified personnel.
- The organization's business, financial condition, operating performance and cash flows may be adversely affected if it undercuts its work orders, exceeds its budgeted costs, fails to obtain approval, or experiences delays in documented change orders.
- There were times when their company failed to comply with its legal obligations. Further late payments of statutory obligations may result in fines from relevant governmental authorities, which could materially adversely affect their cash flows and financial condition.
Also Read: Indegene IPO starts next week. GMP, valuation, price, more details about the upcoming IPO in 10 points
Disclaimer: The above views and recommendations are those of individual analysts, experts and brokerage firms, not Mint. We recommend investors consult certified experts before making an investment decision.
Discover a world of benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized news feed – it's all here, just a click away! Log in now!
Topics that might interest you
Comments are closed.